Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | BCL6 | P41182 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28067981 | 0.83 | MAPT (0.32) | MAPT | |
| SCHEMBL29447613 | 0.83 | CYP11B1 (0.35) | CYP11B1CYP11B2NR3C1PGR | |
| SCHEMBL20401326 | 0.78 | ACSS2 (0.39) | MAPTNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL14895594 | 0.77 | PDPK1 (0.43) | — | |
| SCHEMBL20401501 | 0.76 | CYP11B1 (0.30) | CYP11B1CYP11B2 | |
| SCHEMBL29447640 | 0.74 | ABCC9 (0.38) | NR3C1PGRNPC1RAB9A | |
| SCHEMBL18113496 | 0.73 | RECQL (0.44) | CYP11B1CYP11B2MAPTHPGDRAB9A | |
| SCHEMBL30554368 | 0.73 | RECQL (0.44) | CYP11B1CYP11B2MAPTHPGDRAB9A | |
| SCHEMBL20401381 | 0.72 | HTR2A (0.30) | — | |
| SCHEMBL23901367 | 0.72 | HDAC8 (0.41) | CYP11B1CYP11B2NR3C1PGRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | CYP11B1 2008/4885CYP11B2 1323/4885NR3C1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.